Clinical And Economic Burden Of Eosinophilic COPD In A Large Retrospective US Cohort

Area of Science:

• Pulmonology
• Health Economics
• Clinical Biomarkers

Background:

• Chronic Obstructive Pulmonary Disease (COPD) poses a significant global health burden.
• Blood eosinophil (EOS) counts are increasingly recognized as potential biomarkers in respiratory diseases.
• Understanding the clinical and economic impact of EOS levels in COPD is crucial for patient management.

Purpose of the Study:

• To investigate the association between blood eosinophil (EOS) counts and clinical outcomes in COPD patients.
• To evaluate the economic impact, including healthcare resource utilization and costs, associated with different EOS levels in COPD.

Main Methods:

• Retrospective cohort study using electronic medical records (EMR) and claims data.
• Analysis of COPD patients' data from January 2014 to March 2016.
• Categorization of patients based on blood EOS counts (≥220 cells/µL vs. <220 cells/µL) and assessment of exacerbations and costs.

Main Results:

• Patients with EOS counts ≥220 cells/µL had higher rates of moderate and severe COPD exacerbations compared to those with EOS <220 cells/µL.
• Increased EOS count was significantly associated with higher total all-cause and COPD-related healthcare costs.
• COPD-related costs were substantially greater in patients with EOS ≥220 cells/µL, driven by increased hospitalizations, office visits, and pharmacy use.

Conclusions:

• COPD patients with blood eosinophil counts of ≥220 cells/µL experience more frequent moderate/severe exacerbations.
• Elevated EOS levels in COPD are associated with significantly greater healthcare costs and resource utilization.
• Blood eosinophil count serves as a valuable indicator for predicting exacerbation risk and healthcare expenditure in COPD patients.